Seller record · Telehealth service

Claya

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S4, compounding disclosure: No page states that the compounded medications are not FDA-approved. The semaglutide page sells compounded semaglutide as a drug also marketed under the brand names Ozempic and Wegovy, and the home page notice says only that compounded medications are not evaluated by the FDA for safety or efficacy. 1 more criterion also fails; see the table below.

At a glance

ClayaTelehealth service

6/8criteria passed

Price: Semaglutide from $149 a month, tirzepatide from $199
Sells: compounded semaglutide injections, compounded semaglutide tablets, and 5 more
FDA letters: None on file

Visit Claya See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth weight loss program selling compounded semaglutide injections and tablets and compounded tirzepatide, with brand GLP-1 pens also listed, care from a contracted telehealth network and a care coaching membership. Care starts with a three-minute online assessment, and the footer names two partner pharmacies.

Operating entity No legal entity name appears in the footer, on the contact page, in the terms of use or in the privacy policy; each names the company only as Claya.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Claya's website; Claya's how it works page
S2	Prescription gating	PASS	Claya's website; Claya's how it works page
S3	Pharmacy identification	PASS	Claya's website; Claya's how it works page
S4	Compounding disclosure	FAIL	Claya's semaglutide page; Claya's website
S5	Analytical documentation	FAIL	Claya's semaglutide page; Claya's important safety information page
S6	Business address	PASS	Claya's website; Claya's terms of use page
S7	Price disclosure	PASS	Claya's website; Claya's semaglutide page; Claya's Zepbound page
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed provider reviews every assessment and creates a treatment plan only if appropriate, and medication ships only if prescribed.Source: Claya's website; Claya's how it works page.

S2PASSThe home page sets out the order as a three-minute online assessment first, then a licensed provider's review, then shipping only if prescribed, and says plan options are shown before checkout.Source: Claya's website; Claya's how it works page.

S3PASSThe footer of every page lists two partner pharmacies with street addresses: RedRock Pharmacy, 1240 E 100 S #220, St. George, UT 84790, and a pharmacy printed as Healthware House, the Health Warehouse pharmacy at 7107 Industrial Rd., Florence, KY 41042.Source: Claya's website; Claya's how it works page.

S4FAILNo page states that the compounded medications are not FDA-approved. The semaglutide page sells compounded semaglutide as a drug also marketed under the brand names Ozempic and Wegovy, and the home page notice says only that compounded medications are not evaluated by the FDA for safety or efficacy.Source: Claya's semaglutide page; Claya's website.

S5FAILNo certificate of analysis or lot document is published on the home page, the semaglutide page, the safety information page or the terms.Source: Claya's semaglutide page; Claya's important safety information page.

S6PASS2345 Via Inspirada, Unit 130, Henderson, NV 89044, printed in the footer of every page, with no legal entity named beside it. The terms give a separate Highlands Ranch, Colorado address for the copyright agent and name Delaware law.Source: Claya's website; Claya's terms of use page.

S7PASSThe home page prints compounded semaglutide from $149 a month and compounded tirzepatide from $199 a month, each on select multi-month plans. The semaglutide page instead prints injections from $179 and tablets from $279 a month, and a treatments page lists the Zepbound and Mounjaro pens at $1,399 a month, the Ozempic pen at $1,299 and the membership at $49 a month.Source: Claya's website; Claya's semaglutide page; Claya's Zepbound page.

S8PASSNo FDA warning letter names Claya, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide injections, compounded semaglutide tablets, compounded tirzepatide, Zepbound pen, Ozempic pen, Mounjaro pen, care coaching membership.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Visit Claya

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.